Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024 JERUSALEM, June 03, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins,...

Modern Times Group MTG AB: Conference Call Announcement -- Financial Results for the Period of January - September 2002 STOCKHOLM, Sweden, Oct. 16, 2002 (PRIMEZONE) -- Modern Times Group MTG AB (Nasdaq:MTGNY) today announced that the conference call is scheduled for Wednesday, October 23, 2002, 11 a.m. (EST -- New...